Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Groenland · SciRah

Researcher profile · Semantic Scholar

S. Groenland

Share profile

S. Groenland — researcher profile on SciRah

h-index: 16
Works: 47
Citations: 930

Most-cited papers

Therapeutic drug monitoring of oral targeted antineoplastic drugs
Anna Mueller‐Schoell, S. Groenland, Oliver Scherf-Clavel, Madelé van Dyk +6 more
2020European Journal of Clinical Pharmacology179 citations Open access
Semantic Scholar
Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib
S. Groenland, Alejandra Martínez-Chávez, M. V. van Dongen, J. Beijnen +3 more
2020Clinical Pharmacokinetics97 citations Open access
Semantic Scholar
Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine
S. Groenland, R. Mathijssen, J. Beijnen, A. Huitema +1 more
2019European Journal of Clinical Pharmacology91 citations Open access
Semantic Scholar
Therapeutic drug monitoring based precision dosing of oral targeted therapies in oncology: a prospective multicentre study.
S. Groenland, R. A. G. van Eerden, K. Westerdijk, M. Meertens +14 more
2022Annals of Oncology67 citations Open access
Semantic Scholar
Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non‐Small Cell Lung Cancer Patients
S. Groenland, D. R. Geel, J. Janssen, N. de Vries +6 more
2020Clinical pharmacology and therapy45 citations Open access
Semantic Scholar
Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology
S. Groenland, M. van Nuland, R. Verheijen, J. Schellens +3 more
2018Clinical Pharmacokinetics42 citations Open access
Semantic Scholar
Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Group-Therapeutic Drug Monitoring Protocol for a Prospective Study.
S. Groenland, R. A. G. van Eerden, R. Verheijen, S. Koolen +8 more
2019Therapeutic Drug Monitoring40 citations Open access
Semantic Scholar
Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours - Results from daily clinical practice.
N. Ijzerman, S. Groenland, A. Koenen, M. Kerst +5 more
2020European Journal of Cancer31 citations
Semantic Scholar
Solubility and bioavailability improvement of pazopanib hydrochloride
M. Herbrink, S. Groenland, A. Huitema, J. Schellens +3 more
2018International journal of pharmaceutics30 citations Open access
Semantic Scholar
Precision Dosing of Targeted Therapies is Ready for Prime Time
S. Groenland, R. Verheijen, M. Joerger, R. Mathijssen +5 more
2021Clinical Cancer Research28 citations Open access
Semantic Scholar
Inducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results from INDUCE-1 expansion cohorts (EC) in head and neck squamous cell carcinoma (HNSCC)
D. Rischin, S. Groenland, A. Lim, J. Martin-Liberal +16 more
2019Annals of Oncology21 citations Open access
Semantic Scholar
Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme.
S. Groenland, M. van Nuland, A. Bergman, J. D. de Feijter +5 more
2020European Journal of Cancer20 citations Open access
Semantic Scholar
Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer
S. Krens, N. V. van Erp, S. Groenland, D. J. Moes +5 more
2022BMC Cancer19 citations Open access
Semantic Scholar
Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting
R. Boosman, M. Jebbink, W. Veldhuis, S. Groenland +7 more
2022Pharmaceutical Research17 citations Open access
Semantic Scholar
Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol
Anna M. Mc Laughlin, E. Schmulenson, O. Teplytska, S. Zimmermann +15 more
2021Cancers16 citations Open access
Semantic Scholar
Updated analysis of the inducible T-cell co-stimulatory receptor (ICOS) agonist, GSK3359609 (GSK609), combination with pembrolizumab (PE) in patients (pts) with anti-PD-1/L1 treatment-naïve head and neck squamous cell carcinoma (HNSCC).
E. Angevin, S. Groenland, A. Lim, J. Martin-Liberal +16 more
202016 citations
Semantic Scholar
Relation between duration of the prodromal phase and renal damage in ANCA-associated vasculitis
E. Houben, S. Groenland, J. W. van der Heijden, A. Voskuyl +2 more
2017BMC Nephrology13 citations Open access
Semantic Scholar
Safety and tolerability of MEDI0562, an OX40 agonist monoclonal antibody, in combination with durvalumab or tremelimumab in adult patients with advanced solid tumors.
J. Goldman, S. Piha-Paul, B. Curti, K. Pedersen +13 more
2022Clinical Cancer Research12 citations Open access
Semantic Scholar
Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer
Laura Molenaar-Kuijsten, C. L. Braal, S. Groenland, N. de Vries +8 more
2021Clinical pharmacology and therapy12 citations Open access
Semantic Scholar
Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
J. Goldman, S. Piha-Paul, B. Curti, K. Pedersen +11 more
202012 citations
Semantic Scholar
Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib
R. Boosman, C. D. De Gooijer, S. Groenland, J. Burgers +5 more
2022Pharmaceutical Research11 citations Open access
Semantic Scholar
The Right Dose: From Phase I to Clinical Practice.
S. Groenland, M. Ratain, Lisa S. Chen, V. Gandhi
2021American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting11 citations Open access
Semantic Scholar
Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology – an analysis of the closed cohorts of a multicentre prospective study
Maud B. A. van der Kleij, N. A. D. Guchelaar, M. Meertens, K. Westerdijk +19 more
2024British Journal of Cancer10 citations Open access
Semantic Scholar
Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer.
N. A. D. Guchelaar, R. A. G. van Eerden, S. Groenland, L. van Doorn +7 more
2022Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie10 citations Open access
Semantic Scholar
Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer Patients
S. Groenland, R. A. G. van Eerden, R. Verheijen, N. de Vries +7 more
2020Clinical Pharmacokinetics10 citations Open access
Semantic Scholar
Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose
J. Roosendaal, S. Groenland, H. Rosing, L. Lucas +5 more
2020European Journal of Clinical Pharmacology9 citations Open access
Semantic Scholar
First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1.
A. Hansen, T. Bauer, V. Moreno, M. Maio +16 more
2018Annals of Oncology9 citations Open access
Semantic Scholar
Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients
S. Groenland, J. Janssen, C. Nijenhuis, N. de Vries +8 more
2023Cancer Chemotherapy and Pharmacology8 citations
Semantic Scholar
Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels
S. Groenland, D. Katz, A. Huitema, N. Steeghs
2018BMC Cancer7 citations Open access
Semantic Scholar
Feasibility and efficacy of therapeutic drug monitoring of abiraterone in metastatic castration resistant prostate cancer patients
Maud B. A. van der Kleij, M. Meertens, S. Groenland, S. Kordes +4 more
2025British Journal of Cancer5 citations Open access
Semantic Scholar
1O Inducible T cell co-stimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and combination with pembrolizumab: Preliminary results from INDUCE-1 expansion cohorts in head and neck squamous cell carcinoma (HNSCC)
C. le Tourneau, D. Rischin, S. Groenland, A. Lim +16 more
2020Annals of Oncology5 citations Open access
Semantic Scholar
567P Exposure-response analyses of dabrafenib and trametinib in melanoma patients
S. Groenland, J. Janssen, C. Nijenhuis, N. de Vries +8 more
20205 citations Open access
Semantic Scholar
Correction to: Therapeutic drug monitoring of oral targeted antineoplastic drugs
Anna Mueller‐Schoell, S. Groenland, Oliver Scherf-Clavel, Madelé van Dyk +6 more
2020European Journal of Clinical Pharmacology4 citations Open access
Semantic Scholar
Boosting pazopanib exposure by splitting intake moments: A prospective pharmacokinetic study in cancer patients.
S. Groenland, R. A. G. van Eerden, R. Verheijen, A. Huitema +2 more
2019Journal of Clinical Oncology4 citations
Semantic Scholar
Therapeutic drug monitoring of oral anticancer drugs - preliminary results of a prospective study
S. Groenland, R. A. G. van Eerden, S. Koolen, D. J. Moes +9 more
2019Annals of Oncology3 citations Open access
Semantic Scholar
Exposure-response analyses of ALK-inhibitors crizotinib and alectinib in NSCLC patients
S. Groenland, D. R. Geel, J. Janssen, J. Beijnen +4 more
2019Annals of Oncology3 citations Open access
Semantic Scholar
Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer
S. Krens, N. V. van Erp, S. Groenland, D. J. Moes +5 more
2022BMC Cancer2 citations Open access
Semantic Scholar
Response to “Optimized Alectinib Dose Regimen for Treatment of Patients With ALK‐Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence”
S. Groenland, D. R. Geel, J. Beijnen, E. Smit +2 more
2021Clinical pharmacology and therapy2 citations Open access
Semantic Scholar
Therapeutic drug monitoring of pazopanib: Using cost-neutral PK-guided interventions to optimize exposure.
S. Groenland, R. A. G. van Eerden, S. Koolen, D. J. Moes +8 more
2020Journal of Clinical Oncology2 citations
Semantic Scholar
Concomitant intake of abiraterone and food to increase pharmacokinetic exposure: Real-life data from a therapeutic drug monitoring program.
S. Groenland, A. Bergman, A. Huitema, N. Steeghs
2019Journal of Clinical Oncology2 citations
Semantic Scholar
Incidence of clinically significant toxicities in patients with high endoxifen concentrations.
S. Groenland, A. Sanchez-Spitman, D. Moes, S. Koolen +6 more
2018Annals of Oncology2 citations Open access
Semantic Scholar
Plasma concentration guided dosing of drugs used for the treatment of childhood leukaemias: protocol for a systematic review
Madelé van Dyk, Chelsea Boylan, R. Michelet, Anna M. Mc Laughlin +10 more
2022BMJ Open0 citations Open access
Semantic Scholar
Optimizing exposure of oral targeted therapies in oncology : Towards precision dosing
S. Groenland
20210 citations Open access
Semantic Scholar
537P-SC Exposure-response analysis of cabozantinib in patients with metastatic renal cell cancer treated in routine care
S. Krens, N. V. van Erp, S. Groenland, D. Moes +5 more
2021Annals of Oncology0 citations Open access
Semantic Scholar
Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose
J. Roosendaal, S. Groenland, H. Rosing, L. Lucas +5 more
2020European Journal of Clinical Pharmacology0 citations Open access
Semantic Scholar
11P Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study
E. Angevin, S. Groenland, T. Bauer, D. Rischin +15 more
2020Annals of Oncology0 citations Open access
Semantic Scholar
Solubility and Bioavailability Improvement of Pazopanib Hydrochloride ( PZH )
M. Herbrink, S. Groenland, N. Steeghs, A. Huitema +3 more
20170 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. Steeghs×34
Invite
N. Steeghs — researcher profile on SciRah
A. Huitema×21
Invite
A. Huitema — researcher profile on SciRah
J. Beijnen×19
Invite
J. Beijnen — researcher profile on SciRah
A. Huitema×12
Invite
A. Huitema — researcher profile on SciRah

×10

Invite

H. Rosing — researcher profile on SciRah

Invite

S. Koolen — researcher profile on SciRah

N. V. van Erp×9

Invite

N. V. van Erp — researcher profile on SciRah

R. A. G. van Eerden×8

Invite

R. A. G. van Eerden — researcher profile on SciRah

Invite

I. Desar — researcher profile on SciRah

R. Mathijssen×7

Invite

R. Mathijssen — researcher profile on SciRah

Invite

D. J. Moes — researcher profile on SciRah

Invite

N. de Vries — researcher profile on SciRah